Journal of Pharmacology and Experimental Therapeutics
ISSN 0022-3565 · American Society for Pharmacology and Experimental Therapeutics · United States · active 1909–2026
Metrics
- Scimago quartile (2025)
- Q2
- Cites per paper (2y)
- 1.0
- SJR
- 0.921
- h-index
- 325
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric (how the two differ). Citation rates differ enormously between fields, so compare within a discipline. What the other figures mean: journal quartile, SJR, h-index and article processing charge.
Data as of 15 November 2026 (venue index build).
Scimago Journal Rank 2025
In the Scimago Journal Rank 2025 edition, Journal of Pharmacology and Experimental Therapeutics is Q2 in all 2 of its subject categories.
| Subject category | Quartile | Rank in category |
|---|---|---|
| Molecular Medicine | Q2 | #71 of 181 |
| Pharmacology | Q2 | #97 of 339 |
- Cites per document (2 years, Scopus)
- 3.40
- Documents indexed in 2025 (Scopus)
- 287
OpenAlex counts about 1.0 citations per paper over two years; Scopus, through Scimago, counts 3.40 per document. The two databases index different journals, documents and citations, so the figures differ. Neither is a Clarivate Journal Impact Factor.
The quartile is the one Scimago prints for each category. Rank is the journal's position by SJR among the journals Scimago lists in that category (#1 is the highest); “—” means we hold no rank consistent with that quartile. The document count is what Scopus indexed that year, which can be lower than a journal's full output. Source: SCImago Journal Rank 2025 edition, from Scopus data (scimagojr.com, CC BY-NC).
Journal of Pharmacology and Experimental Therapeutics is Q2 in all 2 of its Scimago subject categories (2025 edition; best category Molecular Medicine: Q2, #71 of 181), with SJR 0.921 (Scimago) and an h-index of 325 (OpenAlex). Listed in Scopus, Web of Science, PubMed.
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Indexing & access
- Indexed in
- ScopusWeb of SciencePubMed
- Access status:
- hybrid. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Journal of Pharmacology and Experimental Therapeutics a predatory journal?
Our screening does not flag Journal of Pharmacology and Experimental Therapeutics. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.
Is Journal of Pharmacology and Experimental Therapeutics indexed in Scopus or Web of Science?
Per our venue index, Journal of Pharmacology and Experimental Therapeutics appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of Journal of Pharmacology and Experimental Therapeutics?
Papers in Journal of Pharmacology and Experimental Therapeutics are cited about 1.0 times each within two years of publication, and Scimago places it in Q2, with an h-index of 325. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is Journal of Pharmacology and Experimental Therapeutics (Q1, Q2, Q3, or Q4)?
In the Scimago Journal Rank 2025 edition, Journal of Pharmacology and Experimental Therapeutics is Q2 in all 2 of its subject categories. By category: Molecular Medicine: Q2, #71 of 181; Pharmacology: Q2, #97 of 339. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Journal of Pharmacology and Experimental Therapeutics is cited about 1.0 times per paper over two years, with an h-index of 325.
What is the Web of Science (JCR) quartile of Journal of Pharmacology and Experimental Therapeutics?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Journal of Pharmacology and Experimental Therapeutics. The open equivalent is its Scimago quartile, Q2, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is Journal of Pharmacology and Experimental Therapeutics open access?
Our index records its access status as "hybrid". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
Ready to submit? Tools for your next paper
Similar venues
- Acta Neurobiologiae ExperimentalisQ3 · Nencki Institute of Experimental Biology
- Restorative Neurology and NeuroscienceQ3 · IOS Press
- Journal of Evolutionary Biochemistry and Physiology— · Pleiades Publishing
- Journal of NeurogeneticsQ3 · Taylor & Francis
- The International Journal of NeuropsychopharmacologyQ1 · University of Oxford
- Bulletin of Experimental Biology and MedicineQ3 · Springer Science+Business Media
Compare it with its peers: Ranked Cellular and Molecular Neuroscience journals — ranked by Scimago quartile and cites per paper, predatory venues excluded.